Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update
{{output}}
Introduction: Trk inhibitors are significant in the realm of personalized medicine as they target specific genetic alterations, such as NTRK gene fusions, leading to improved treatment outcomes for cancer patients. By tailoring t... ...